Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
|Articles|January 2, 2022
- Pharmaceutical Technology, January 2022 Issue
- Volume 46
- Issue 1
Sustainable Biowaste Treatment System
Author(s)Pharmaceutical Technology Editors
The MicroEDS BioWaste Treatment System can process between 150 to 500 L of waster per day.
Suncombe’s MicroEDS BioWaste Treatment System is a biologically hazardous waste decontamination unit that can process between 150 to 500 L of waste per day. The low-volume system is certified to ASME and ISO/EN standards for treating biosafety level 1, 2, and 3 waste through an innovative batch process that allows for the positive release of all collected waste.
Advances in the MicroEDS include thermal energy regeneration, low energy usage, and 100% positive release for treated waste and electronic records generation. The system is designed to operate at a thermal treatment parameter of 121 °C for 15 minutes, as well as variable temperature, time and f0 lethality settings, for specific requirements.
According to Suncombe, the new unit delivers at least 61% energy saving relative to prior models and can reduce energy usage and utility consumption by up to 75%. Additionally, based on average use, it reduces the carbon footprint by up to 1.68 tons of carbon dioxide each year.
Articles in this issue
almost 5 years ago
Industrious Pharmaceuticalsalmost 5 years ago
The Long Path to Normalalmost 5 years ago
Changes Afoot: 2022 Outlook for Pharma and its Peoplealmost 5 years ago
Addressing the Training Gap for Single-Use Technologiesalmost 5 years ago
The Need for Speed: How Operation Warp Speed Shifted the Pharma Industryalmost 5 years ago
Taste and Appearance: Selecting the Right Excipientsalmost 5 years ago
Tackling the Big Issue of Solubilityalmost 5 years ago
Biologics Testing Highlights Need for Analytical Skillsalmost 5 years ago
Outsourcing’s Race Toward Noveltyalmost 5 years ago
Regulating Digital TherapeuticsRelated to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.